Related Experiment Video
Updated: May 27, 2026
10:31
Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
Juvenile myasthenia gravis: a paediatric perspective
Maria F Finnis1, Sandeep Jayawant
1Department of Paediatric Neurology, Children's Hospital, John Radcliffe Hospital, Oxford OX3 9DU, UK.
Autoimmune Diseases
|November 24, 2011
Summary
Juvenile myasthenia gravis (JMG) is a rare autoimmune condition in children, distinct from adult forms. Early diagnosis and tailored treatments considering developmental needs are crucial for managing JMG effectively.
Area of Science:
- Neurology
- Immunology
- Pediatrics
Background:
- Myasthenia gravis (MG) is an autoimmune disorder affecting the neuromuscular junction.
- Juvenile myasthenia gravis (JMG) presents unique clinical features in children, differing from adult MG.
- Distinguishing JMG from congenital myasthenic syndromes is critical for accurate diagnosis.
Purpose of the Study:
- To outline the distinct characteristics of juvenile myasthenia gravis.
- To discuss diagnostic challenges and therapeutic strategies for JMG.
- To emphasize the importance of considering developmental factors in JMG management.
Main Methods:
- Review of clinical features, diagnostic criteria, and treatment modalities for JMG.
- Comparison of JMG presentation with adult-onset MG.
- Analysis of therapeutic outcomes including medications, plasma exchange, IVIG, and thymectomy.
Main Results:
- Prepubertal children with JMG often exhibit isolated ocular symptoms and lower acetylcholine receptor antibody frequency.
- Children with JMG have a higher likelihood of achieving remission compared to adults.
- Anticholinesterases, corticosteroids, immune modulators, plasma exchange, IVIG, and thymectomy are key treatment options.
Conclusions:
- JMG requires a distinct approach to diagnosis and management in pediatric patients.
- Treatment strategies must be individualized, accounting for developmental needs and potential side effects.
- Thymectomy can improve remission rates in JMG patients.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:28Disorders of the Skeletal Muscle
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:20Asthma: Pathogenesis and Management
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...